Novartis Ag (NVS) Other financing activities (2009 - 2026)

Novartis Ag has disclosed Other financing activities across 18 years of filings, most recently posting -$67.0 million for Q2 2026.

• In Q2 2026, Other financing activities rose 68.84% year-over-year to -$67.0 million; the TTM figure through Jun 2026 stood at -$159.0 million (down 35.9% YoY), while the FY2025 annual figure was -$203.0 million, down 336.05% from the prior year.
• Other financing activities came in at -$67.0 million for Q2 2026 at Novartis Ag, down from $78.0 million in the prior quarter.
• In the past five years, Other financing activities ranged from a high of $3.5 billion in Q3 2023 to a low of -$215.0 million in Q2 2025.
• Average Other financing activities over 5 years is $166.1 million, with a median of $22.0 million recorded in 2022.
• Year-over-year, Other financing activities plunged 2783.33% in 2022 and soared 10756.25% in 2023.
• Over 5 years, Other financing activities stood at -$161.0 million in 2022, then jumped by 31.06% to -$111.0 million in 2023, then jumped by 125.23% to $28.0 million in 2024, then slumped by 785.71% to -$192.0 million in 2025, then soared by 65.1% to -$67.0 million in 2026.
• Per Business Quant data, the three most recent Other financing activities figures were -$67.0 million in Q2 2026, $78.0 million in Q1 2026, and -$192.0 million in Q4 2025.